Unentdeckte Biotech-Perle aus Aussi-Land? - 500 Beiträge pro Seite

[nonnenkloster]

Es wird Zeit, einmal auf diese Biotechaktie aus Australien hinzuweisen: Xceed Biotechnology (WKN A0CBF5), Börse: www.asx.com.au, Kürzel XBL.

Leider wird sie unter WO noch als Southpointe geführt- eventuell ist deshalb die Aufmerksamkeit an dieser Perle bisher an vielen vorbeigerauscht. Bevor ihr weiter lest: natürlich ist das hier ein Push-Thread.

Aber: Wenn innerhalb kürzester Zeit der CEO ca. 225.000 Aktien erwirbt (1.9.04 + 2.9.04) und der AR ca. 150.000 (2.9.04) Aktien hinzukauft, dann ist hier in meinen Augen in jedem Fall ein Potenzial zusehen. Zur Info über das Geschäftsfeld von Xceed, hier ein paar Meldungen der letzten Monate:

24.05.2004

Breakthrough polymer for bone repair

A breakthrough in polymer development means that soon there may be a radical new treatment for people with broken bones - a special kind of material that can ’glue’ the bone back together and support it while it heals.

The material is designed to break down as the bone regrows leaving only natural tissue.

Scientists at CSIRO Molecular Science have developed a biodegradable polymer that can be used in the human body. Not only is it biodegradable and biocom-patible, it can be formulated as an injectable gel which cures in-situ or on-demand by promoting tissue growth. The polymer’s rate of degradation can also be controlled.

" Synthetic polymers offer a number of advantages over ceramic and natural polymer-based materials," says CSIRO Molecular Science Chief, Dr Annabelle Duncan,

" We envisage that this polymer technology could be tailored for applications in orthopaedics, orthodontics, drug delivery, wound care, tissue engineering and cartilage repair," Dr Duncan says

One of the inventors of the polymer, Dr Thilak Gunatillake, plans to apply it ini-tially in the form of a bone glue for fracture repair.

He says that the material has a distinct advantage in this area due to its combi-nation of injectability, adhesiveness and excellent mechanical strength.

Further research is planned to demonstrate the polymer’s ability to deliver cells or biological agents to accelerate tissue regrowth.

" The use of the polymer for guided bone regrowth is not only applicable to the orthopaedic area, but also in related applications such as periodontal surgery and dental implants" , Dr Gunatillake says.

A spin-off company, Polymerco Pty Ltd, has been established by CSIRO and Xceed Biotechnology to develop this revolutionary new biodegrad-able polymer technology for medical device applications.

" Xceed will invest $5.1 million into Polymerco and both CSIRO and Xceed will own 50 per cent," says the Chief Executive Officer of Xceed Biotechnology, Mr David McAuliffe,

" The formation of PolymerCo Pty Ltd is an exciting development and an example of CSIRO’s commercialisation strategy in action. We are looking forward to a profitable relationship with CSIRO as we progress the tech-nology through to products."

CSIRO and Polymerco inventors are presenting papers on the new tech-nology at the 7thWorld Biomaterials Congress in Sydney from 17 to 21 May, 2004.


10 June 2004

MEDIA RELEASE

POLYMERCO FORMS AN ALLIANCE WITH AORTECH BIOMATERIALS

Xceed Biotechnology Ltd (“Xceed”) is pleased to announce Polymerco Pty Ltd (“Polymerco”) and AorTech Biomaterials (“Aortech”) have entered into an agreement under which Polymerco’s novel biodegradable polyurethane technol-ogy will be scaled-up, stabilised and manufactured at AorTech’s ISO certified Melbourne Australia Technology Centre. Polymerco is an operating subsidiary of Xceed that has acquired a license to a revolutionary biodegradable polyurethane technology from CSIRO. It is envisaged that this material will find applications in orthopaedics, wound repair, drug delivery and stents. Dr Ian Griffiths, (CEO Po-lymerco), said ‘We are delighted to reach a general agreement with AorTech and after some applied development work Polymerco will be ready to engage the considerable talents of the AorTech group.’ AorTech Biomaterials is a Melbourne based manufacturer of the biostable polyurethane technology Elast-Eon, which is currently being supplied into numerous medical device development pro-grammes. AorTech has licences with major medical device company’s in the fields of cardiovascular surgery and interventional cardiology. Access to the skills, equipment and personnel already established by AorTech for the manufac-ture of materials used in critical long term implants will ensure the rapid scale-up and supply of the new polymer technology.


19 July 2004

ASX / MEDIA RELEASE


PolyNovo Biomaterials forms Research Alliance with Imperial College London, UK


PolyNovo Biomaterials Pty Ltd (“PolyNovo”) is pleased to announce it has formed an alliance with Imperial College London, UK to further develop aspects of its no-vel polymer technology for bone repair.

Dr Ian Griffiths, Chief Executive Officer of PolyNovo, said “We are delighted to be collaborating with such a prestigious academic group and look forward to the ad-ditional product benefits that may emerge”.

Dr Molly Stevens leading the research at Imperial College’s Department of Mate-rials said ”We are very excited to explore the potential orthopaedic applications of the novel polymer technology. We believe that there is great potential for the-se new materials in the regeneration of complex hard tissues such as bone due to the optimised environment they provide for tissue formation”.

Consistently rated in the top three UK university institutions, Imperial College London is a world leading science-based university whose reputation for excel-lence in teaching and research attracts students (11,000) and staff (6,000) of the highest international quality. Innovative research at the College explores the interface between science, medicine, engineering and management and delivers practical solutions that enhance the quality of life and the environment - under-pinned by a dynamic enterprise culture.

-ENDS-

[hanszwengel]

Wieder so ne Hightech Aussi Aktie von dem Betrügerpack aus Down Under

Finger Weg

[nonnenkloster]

In Australien heute + 5,4 %

[nonnenkloster]

Insidertransaktionen haben unverkennbare Signalwirkung Dass Insider - und hier vor allem Vorstandsmitglieder - ihre eigenen Firmen am besten kennen und somit einen Wissensvorsprung besitzen, ist wohlbekannt. Und dass auch Insider mit ihren Käufen Geld verdienen wollen, ist wohl ebenso einleuchtend. Blindes Nachkaufen bringt jedoch nicht immer den gewünschten Erfolg, denn vor allem kleinere Insiderkäufe können oftmals nur zu Marketingzwecken eingesetzt werden. Oftmals ist jedoch festzustellen, dass insbesondere auf grössere Insiderkäufe von Vorständen Kursanstiege folgen.

Es lohnt sich, Insiderdaten regelmässig zu verfolgen. Wenn dann das Geschäftsmodell noch zweistellige Wachstumsraten verspricht und die Bewertung stimmt, sollten sich Käufe auszahlen.